Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCan PharmaHAM:IP40 +8.48%58 Earnings Yield (Joel Greenblatt) % is -2.81% as of Mar. 2026. GuruFocus rates HAM:IP40 with a GF Score™ of 58/100 and a GF Value™ of €9.78 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 2,033 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 90.11% on this metric.
InnoCan Pharma's Enterprise Value for the quarter that ended in Mar. 2026 was €16.03 Mil.
InnoCan Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.47 Mil. InnoCan Pharma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -2.81%.
The historical rank and industry rank for InnoCan Pharma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
HAM:IP40'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -23.49 Med: -7.65 Max: 4.12
Current: -7.71
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of InnoCan Pharma was 4.12%. The lowest was -23.49%. And the median was -7.65%.
HAM:IP40's Earnings Yield (Joel Greenblatt) % is ranked worse than 90.11% of 2033
companies
in the Consumer Packaged Goods industry
Industry Median: 6.03
vs HAM:IP40: -7.71
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. InnoCan Pharma's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
InnoCan Pharma Earnings Yield (Joel Greenblatt) % Related Terms
InnoCan Pharma Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Earnings Yield (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
InnoCan Pharmas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
InnoCan Pharma's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.47 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -2.81% mean?
InnoCan Pharma (HAM:IP40) has a Earnings Yield (Joel Greenblatt) % of -2.81% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1832 out of 2033 companies in the Consumer Packaged Goods industry, placing it in the top 90.1%.
Is InnoCan Pharma's Earnings Yield (Joel Greenblatt) % too high?
InnoCan Pharma's current Earnings Yield (Joel Greenblatt) % is -2.81%. Based on the distribution chart, InnoCan Pharma ranks #1832 out of 2033 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Earnings Yield (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1832 out of 2033 companies for Earnings Yield (Joel Greenblatt) %. This places InnoCan Pharma in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 6.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median Earnings Yield (Joel Greenblatt) % among Consumer Packaged Goods companies is 6.03, based on 2,033 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Earnings Yield (Joel Greenblatt) % is 6.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Earnings Yield (Joel Greenblatt) % is -2.81%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (HAM:IP40) is currently considered Possible Value Trap. The stock's GF Value™ is €9.78, compared to a current price of €1.54 — trading 84.3% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is -2.81%. InnoCan Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For InnoCan Pharma (HAM:IP40), the current Earnings Yield (Joel Greenblatt) % is -2.81% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (HAM:IP40) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of €1.54 is trading 84.3% below its estimated GF Value™ of €9.78.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for HAM:IP40:
Earnings Yield (Joel Greenblatt) %: -2.81%
GF Value™: €9.78 vs. price of €1.54 (84.3% below fair value)
No single metric tells the full story. See the HAM:IP40 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
58GF Score
Get the complete analysis for HAM:IP40
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:IP40 has been successfully added to your 
